|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kudo M, Matsui O, Izumi N, Iijima H,
Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, et
al: JSH consensus-based clinical practice guidelines for the
management of hepatocellular carcinoma: 2014 update by the liver
cancer study group of Japan. Liver Cancer. 3:458–468. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
European Association For The Study Of The
Liver1, . European Organisation For Research And Treatment Of
Cancer: EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ogasawara S, Chiba T, Ooka Y, Kanogawa N,
Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M and Yokosuka
O: Efficacy of sorafenib in intermediate-stage hepatocellular
carcinoma patients refractory to transarterial chemoembolization.
Oncology. 87:330–341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arizumi T, Ueshima K, Minami T, Kono M,
Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, et al:
Effectiveness of sorafenib in patients with transcatheter arterial
chemoembolization (TACE) refractory and intermediate-stage
hepatocellular carcinoma. Liver Cancer. 4:253–262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
NCI common terminology criteria for
adverse events (CTCAE) v.4 data files. http://evs.nci.nih.gov/ftp1/CTCAE/About.htmlMay
14–2015
|
|
9
|
Ikeda M, Arai Y, Park SJ, Takeuchi Y, Anai
H, Kim JK, Inaba Y, Aramaki T, Kwon SH, Yamamoto S, et al:
Prospective study of transcatheter arterial chemoembolization for
unresectable hepatocellular carcinoma: An Asian cooperative study
between Japan and Korea. J Vasc Interv Radiol. 24:490–500. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kudo M, Matsui O, Izumi N, Kadoya M,
Okusaka T, Miyayama S, Yamakado K, Tsuchiya K, Ueshima K, Hiraoka
A, et al: Transarterial chemoembolization failure/refractoriness:
JSH-LCSGJ criteria 2014 update. Oncology. 87 Suppl 1:S22–S31. 2014.
View Article : Google Scholar
|
|
11
|
Ikeda M, Mitsunaga S, Shimizu S, Ohno I,
Takahashi H, Okuyama H, Kuwahara A, Kondo S, Morizane C, Ueno H, et
al: Efficacy of sorafenib in patients with hepatocellular carcinoma
refractory to transcatheter arterial chemoembolization. J
Gastroenterol. 49:932–940. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mise M, Arii S, Higashituji H, Furutani M,
Niwano M, Harada T, Ishigami S, Toda Y, Nakayama H, Fukumoto M, et
al: Clinical significance of vascular endothelial growth factor and
basic fibroblast growth factor gene expression in liver tumor.
Hepatology. 23:455–464. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Suzuki H, Mori M, Kawaguchi C, Adachi M,
Miura S and Ishii H: Serum vascular endothelial growth factor in
the course of transcatheter arterial embolization of hepatocellular
carcinoma. Int J Oncol. 14:1087–1090. 1999.PubMed/NCBI
|
|
15
|
Li X, Feng GS, Zheng CS, Zhuo CK and Liu
X: Expression of plasma vascular endothelial growth factor in
patients with hepatocellular carcinoma and effect of transcatheter
arterial chemoembolization therapy on plasma vascular endothelial
growth factor level. World J Gastroenterol. 10:2878–2882. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Poon RT, Lau C, Pang R, Ng KK, Yuen J and
Fan ST: High serum vascular endothelial growth factor levels
predict poor prognosis after radiofrequency ablation of
hepatocellular carcinoma: Importance of tumor biomarker in ablative
therapies. Ann Surg Oncol. 14:1835–1845. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sergio A, Cristofori C, Cardin R, Pivetta
G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A and
Farinati F: Transcatheter arterial chemoembolization (TACE) in
hepatocellular carcinoma (HCC): The role of angiogenesis and
invasiveness. Am J Gastroenterol. 103:914–921. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shim JH, Park JW, Kim JH, An M, Kong SY,
Nam BH, Choi JI, Kim HB, Lee WJ and Kim CM: Association between
increment of serum VEGF level and prognosis after transcatheter
arterial chemoembolization in hepatocellular carcinoma patients.
Cancer Sci. 99:2037–2044. 2008.PubMed/NCBI
|
|
19
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kudo M, Imanaka K, Chida N, Nakachi K, Tak
WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, et al: Phase
III study of sorafenib after transarterial chemoembolisation in
Japanese and Korean patients with unresectable hepatocellular
carcinoma. Eur J Cancer. 47:2117–2127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sieghart W, Pinter M, Reisegger M, Müller
C, Ba-Ssalamah A, Lammer J and Peck-Radosavljevic M: Conventional
transarterial chemoembolisation in combination with sorafenib for
patients with hepatocellular carcinoma: A pilot study. Eur Radiol.
22:1214–1223. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pawlik TM, Reyes DK, Cosgrove D, Kamel IR,
Bhagat N and Geschwind JF: Phase II trial of sorafenib combined
with concurrent transarterial chemoembolization with drug-eluting
beads for hepatocellular carcinoma. J Clin Oncol. 29:3960–3967.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cabrera R, Pannu DS, Caridi J, Firpi RJ,
Soldevila-Pico C, Morelli G, Clark V, Suman A, George TJ Jr and
Nelson DR: The combination of sorafenib with transarterial
chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol
Ther. 34:205–213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
